Rosenman Institute Launch Symposium
The route for taking a medical device from idea to product generally isn’t smooth. Surgeons know what problems they need solved, but they often know little about bioengineering. Engineers are great at building products, but often don't know whether a device is needed or wanted in the clinic.
That’s why we created the Rosenman Institute, a UCSF-based initiative devoted to medical device innovation. The Institute, named for the late Dan Rosenman, a biomedical engineer, is a collaboration between QB3, the UCSF Department of Surgery, the UCSF Department of Bioengineering and Therapeutic Sciences, and medical device professionals. Our goal is to connect physician innovators with engineering expertise and business support to accelerate medical device innovation.
This symposium will inspire clinicians to innovate; introduce the resources available at the Rosenman Institute; and enable entrepreneurs to share their stories and their perspectives on the future of medical device innovation. It will also provide an opportunity for networking with entrepreneurs, physicians, investors, biomedical engineers, mentors and representatives of major device companies.
- Registration & Networking
- Reg Kelly, PhD, Director, QB3
- Kathy Giacomini, PhD, Chair, UCSF Department of Bioengineering and Therapeutic Sciences
- Hanmin Lee, MD, Surgeon in Chief, UCSF Benioff Children's Hospital San Francisco
- Panel Discussion: "From Ideas to Commercialization: Lessons Learned"
- The Rosenman Fellows
- Moderated by Reg Kelly
- "The Radically Changing Landscape for Medical Technology Innovation," Paul Yock, MD, Director, Biodesign, Stanford University
- "The Innovator's Dilemma in Surgery," Ken Drazan, MD, Head, Johnson & Johnson Innovation Center in California
- Panel Discussion: "Insights on Early Stage Funding"
- Ned Scheetz, Managing Director, Aphelion Capital
- Allan May, Chairman & Founder, Life Science Angels
- Moderated by Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati
- "So You Want to Be an Entrepreneur?," Frank Litvack, MD, serial entrepreneur
- Reception & Networking
Regis Kelly, PhD, Director, QB3
Prior to joining QB3 in 2004, Regis Kelly served as executive vice-chancellor at UCSF; he oversaw the UCSF research enterprise and was also responsible for construction of the new Mission Bay campus. He was chairman of the Bay Area Scientific Innovation Consortium and has served on the boards of the Malaysian Biotechnology Industry Advisory Board, the Scleroderma Foundation, and Bridge Pharmaceuticals. He is an advisor to the Thailand Bionanotechnology Institute, Ho Chi Minh City Biotechnology Department Corp., University of Oxford Systems Biology Program, and the San Francisco Mayor’s Biotechnology Advisory Group. He joined the UCSF Department of Biochemistry in 1971 [ More
Hanmin Lee, MD, Surgeon in Chief, UCSF Benioff Children's Hospital San Francisco
Dr. Lee was an undergraduate at Johns Hopkins University who completed both medical school and general surgery residency at New York University. He did two years of postdoctoral research training under the mentorship of Dr. Jay Vacanti at Harvard Medical School, and two years of pediatric surgery fellowship at Emory University Medical Center before being appointed to a tenure-track faculty position in the Department of Surgery at UCSF in 2000. An expert and pioneer in the area of minimally invasive surgery, Dr. Lee has developed and refined many of the fetal endoscopic techniques now utilized in prenatal intervention, including selective fetoscopic laser surgery in the treatment of twin-twin transfusion syndrome [ More
Kathy Giacomini, PhD, Chair, UCSF Department of Bioengineering and Therapeutic Sciences
Kathleen M. Giacomini, Ph.D., Professor and Chair of the Department of Bioengineering and Therapeutic Sciences, received her Ph.D. in Pharmaceutics from the State University of New York at Buffalo and completed a post-doctoral fellowship at Stanford University. Dr. Giacomini is considered a leader in the field of pharmacogenomics of membrane transporters. She led the discovery of coding region variants of about 50 membrane transporters that play a role in drug response in ethnically diverse populations. Dr. Giacomini has co-authored over 200 manuscripts in peer-reviewed journals and has received many awards for her research [ More
Ken Drazan, MD, Head, Johnson & Johnson Innovation Center in California (JJIC)
Ken Drazan leads the Johnson & Johnson Innovation Center in carrying out the organization’s mission to access early external innovation. Ken’s background includes more than 13 years in the healthcare industry and 12 years in the hospital and academic worlds. Ken works with the California IC Team and partners with the other JJICs and the R&D, business development, and business leaders across Johnson & Johnson to identify, shape and on-board the most promising science and technology opportunities at universities, academic centers, tech- and biotech companies, with the goal of catalyzing early stage innovation and bringing transformative medicines [ More
Frank Litvack, MD, FACC, serial entrepreneur
Dr. Litvack is a native of Canada. He completed medical school and an internal medicine residency at McGill University in Montreal and a Cardiovascular Fellowship at Cedars-Sinai Medical Center in Los Angeles, where he subsequently became Co-Director of the Cardiovascular Intervention Center and Professor of Medicine at UCLA. There he led a prominent clinical and research program known for its excellence in innovation, care and leadership in Translational Medicine. Dr. Litvack was Board certified in Internal Medicine, Cardiovascular Diseases and Interventional Cardiology. He has published more than one hundred research articles and chapters and is the recipient of several awards [ More
Allan W. May, Co-Founder, Life Science Angels
Allan is a founder of Life Science Angels, the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. LSA has invested over $40M in 45 startups and achieved 7 positive exits to date. In 2007, Allan joined renowned inventor, entrepreneur and cardiac surgeon, Dr. Thomas Fogarty, in co-founding Emergent Medical Partners, a venture fund focused on early stage medical device company creation and investing. EMP has invested $55M in 28 startups with 8 positive exits to date. [ More
J. Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati
J. Casey McGlynn, partner at Wilson Sonsini Goodrich & Rosati, joined WSGR in 1978 and formed the Life Sciences Group at the firm in 1990. It is a nationally recognized leader in the representation of startup and emerging growth companies in the life sciences field. Mr. McGlynn has one of the largest practices in the country focused on Medical Devices. Mr. McGlynn has formed, sold and taken public many of the most important medical device companies started during the last 25 years. Mr. McGlynn has extensive hands on experience in helping entrepreneurs form, build, fund and sell their companies. He has helped to form and participated with the boards of companies in all of the major medical device fields [ More
Ned Scheetz, General Partner and Founder, Aphelion Capital
For over two decades, Mr. Scheetz has been an investor in numerous public and private healthcare companies. Mr. Scheetz was a Partner and Managing Director with Piper Jaffray Ventures and a Senior Analyst with Janus Capital. Prior to beginning his investment career, Mr. Scheetz held a number of sales and marketing positions with divisions of Eastman Kodak and Kraft General Foods. Mr. Scheetz has served on a wide variety of corporate and non-profit boards in his career. Mr. Scheetz is an advisory board member with the Center for Medical Device Innovation, and on the business advisory board of The Epilepsy Therapy Development Project. [ More
Paul Yock, MD, Director, Biodesign, Stanford University
Paul Yock is the Martha Meier Weiland Professor of Medicine and Mechanical Engineering (by courtesy) and Founding Co-Chair of Stanford’s Department of Bioengineering. He also holds a courtesy appointment on Operations, Information and Technology in the Stanford School of Business. Dr. Yock is internationally known for his work in inventing, developing and testing new devices, including the Rapid Exchange™ balloon angioplasty system, which is now the primary system in use worldwide. He also invented a Doppler-guided access system known as the Smart Needle™ and PD-Access™. The main focus of Dr. Yock’s research program has been in the field of intravascular ultrasound. [ More